Emerging use of everolimus in the treatment of neuroendocrine tumors

References

• YaoJCHassanMPhanAOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
   PubMed Web of Science ®Google Scholar
• PhanATObergKChoiJNANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)Pancreas201039678479820664476
   PubMed Web of Science ®Google Scholar
• KlimstraDSModlinIRCoppolaDLloydRVSusterSThe pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systemsPancreas201039670771220664470
   PubMed Web of Science ®Google Scholar
• BosmanFTWorld Health Organization, International Agency for Research on CancerWHO Classification of Tumours of the Digestive System4th edLyonIARC Press2010417
   Google Scholar
• RindiGKlöppelGCouvelardATNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading systemVirchows Arch2007451475776217674042
   PubMed Web of Science ®Google Scholar
• RindiGKlöppelGAlhmanHTNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading systemVirchows Arch2006449439540116967267
   PubMed Web of Science ®Google Scholar
• TravisWDBrambillaENicholsonAGThe 2015 World Health Organization classification of lung tumorsJ Thorac Oncol20151091243126026291008
   PubMed Web of Science ®Google Scholar
• CaplinMEBaudinEFerollaPENETS Consensus Conference ParticipantsPulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsAnn Oncol20152681604162025646366
   PubMed Web of Science ®Google Scholar
• ErikssonJStålbergPNilssonASurgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumorsWorld J Surg200832593093818324347
   PubMed Web of Science ®Google Scholar
• MazzagliaPJBerberEMilasMSipersteinAELaparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survivalSurgery20071421101917629995
   PubMed Web of Science ®Google Scholar
• ModlinIMObergKChungDCGastroenteropancreatic neuroendocrine tumoursLancet Oncol200891617218177818
   PubMed Web of Science ®Google Scholar
• RovielloGZanottiLVenturiniSBottiniAGeneraliDRole of targeted agents in neuroendocrine tumors: results from a meta-analysisCancer Biol Ther201617988388827414404
   PubMed Web of Science ®Google Scholar
• PavelMBaudinECouvelardAENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primaryNeuroendocrinology201295215717622262022
   PubMed Web of Science ®Google Scholar
• RinkeAWittenbergMSchade-BrittingerCPROMID Study GroupPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survivalNeuroendocrinology20171041263226731483
   PubMed Web of Science ®Google Scholar
• StrosbergJEl-HaddadGWolinEPhase 3 trial of (177) Lu-Dotatate for midgut neuroendocrine tumorsN Engl J Med2017376212513528076709
   PubMed Web of Science ®Google Scholar
• BerardiRRinaldiSTorniaiMGastrointestinal neuroendocrine tumors: searching the optimal treatment strategy – a literature reviewCrit Rev Oncol Hematol20169826427426643525
   PubMed Web of Science ®Google Scholar
• SmrzDKimM-SZhangSmTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cellsBlood2011118266803681322053105
   PubMed Web of Science ®Google Scholar
• SarbassovDDGuertinDAAliSMSabatiniDMPhosphorylation and regulation of Akt/PKB by the rictor-mTOR complexScience200530757121098110115718470
   PubMed Web of Science ®Google Scholar
• Meric-BernstamFGonzalez-AnguloAMTargeting the mTOR signaling network for cancer therapyJ Clin Oncol200927132278228719332717
   PubMed Web of Science ®Google Scholar
• ZhouBPHuMCMillerSAHER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathwayJ Biol Chem2000275118027803110713122
   PubMed Web of Science ®Google Scholar
• ChungJBachelderRELipscombEAShawLMMercurioAMIntegrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cellsJ Cell Biol2002158116517412105188
   PubMed Web of Science ®Google Scholar
• CuiXZhangPDengWInsulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancerMol Endocrinol200317457558812554765
   PubMed Web of Science ®Google Scholar
• Stemke-HaleKGonzalez-AnguloAMLluchAAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Res200868156084609118676830
   PubMed Web of Science ®Google Scholar
• O’DonnellAFaivreSBurrisHAPhase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumorsJ Clin Oncol200826101588159518332470
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithRHallMNTOR signaling in growth and metabolismCell2006124347148416469695
   PubMed Web of Science ®Google Scholar
• RouxPPBallifBAAnjumRGygiSPBlenisJTumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinaseProc Natl Acad Sci U S A200410137134891349415342917
   PubMed Web of Science ®Google Scholar
• PhungTLZivKDabydeenDPathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinCancer Cell200610215917016904613
   PubMed Web of Science ®Google Scholar
• FlaumNValleJWMansoorWMcNamaraMGEverolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systemsFuture Oncol201612222561257827412069
   PubMed Web of Science ®Google Scholar
• HoughtonPJEverolimusClin Cancer Res20101651368137220179227
   PubMed Web of Science ®Google Scholar
• KirchnerGIMeier-WiedenbachIMannsMPClinical pharmacokinetics of everolimusClin Pharmacokinet2004432839514748618
   PubMed Web of Science ®Google Scholar
• JacobsenWSerkovaNHausenBMorrisREBenetLZChristiansUComparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RADTransplant Proc2001331–251451511266932
   PubMed Web of Science ®Google Scholar
• LevyGAGrantDParadisKCampestriniJSmithTKovarikJMPharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipientsTransplantation200171116016311211186
   PubMed Web of Science ®Google Scholar
• BushnellDLO’DorisioTMO’DorisioMS90Y-edotreotide for metastatic carcinoid refractory to octreotideJ Clin Oncol201028101652165920194865
   PubMed Web of Science ®Google Scholar
• EastonJBHoughtonPJmTOR and cancer therapyOncogene200625486436644617041628
   PubMed Web of Science ®Google Scholar
• BeuvinkIBoulayAFumagalliSThe mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translationCell2005120674775915797377
   PubMed Web of Science ®Google Scholar
• BoulayARudloffJYeJDual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancerClin Cancer Res200511145319532816033851
   PubMed Web of Science ®Google Scholar
• MissiagliaEDalaiIBarbiSPancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathwayJ Clin Oncol201028224525519917848
   PubMed Web of Science ®Google Scholar
• ChanJARyanDPZhuAXPhase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsEndocr Relat Cancer201219561562322736724
   PubMed Web of Science ®Google Scholar
• ChanJAMayerRJJacksonNMalinowskiPReganEKulkeMHPhase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumorsCancer Chemother Pharmacol20137151241124623475104
   PubMed Web of Science ®Google Scholar
• YaoJCPhanATChangDZEfficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II studyJ Clin Oncol200826264311431818779618
   PubMed Web of Science ®Google Scholar
• YaoJCLombard-BohasCBaudinEDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJ Clin Oncol2010281697619933912
   PubMed Web of Science ®Google Scholar
• PavelMEHainsworthJDBaudinERADIANT-2 Study GroupEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet201137898082005201222119496
   PubMed Web of Science ®Google Scholar
• AnthonyLBPavelMEHainsworthJDImpact of previous somatostatin analogue use on the activity of everolimus in patients with advanced neuroendocrine tumors: analysis from the phase III RADIANT-2 trialNeuroendocrinology20151021–2182525824001
   PubMed Web of Science ®Google Scholar
• YaoJCShahMHItoTRAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study GroupEverolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med2011364651452321306238
   PubMed Web of Science ®Google Scholar
• YaoJCPavelMLombard-BohasCEverolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 StudyJ Clin Oncol Epub2016912
   Web of Science ®Google Scholar
• National Cancer Institute [webpage on the Internet]FDA Approval for EverolimusNational Cancer Institute [cited January 17, 2017]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-everolimusAccessed May 22, 2017
   Google Scholar
• YaoJCFazioNSinghSRAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study GroupEverolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyLancet20163871002296897726703889
   PubMed Web of Science ®Google Scholar
• PanzutoFRinzivilloMFazioNReal-world study of everolimus in advanced progressive neuroendocrine tumorsOncologist201419996697425117065
   PubMed Web of Science ®Google Scholar
• KampKGumzBFeeldersRASafety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177LuoctreotateEndocr Relat Cancer201320682583124036133
   PubMed Web of Science ®Google Scholar
• PavelMEStrosbergJRBubuteishvili-PacaudLHealth-related quality of life (HRQoL) in patients with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trialJ Clin Oncol201634 sul;abstre15657
   Web of Science ®Google Scholar
• SinghSStrosbergJRBubuteishvili-PacaudLHealth-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trialJ Clin Oncol201735 sul4S;abstract285
   Web of Science ®Google Scholar
• Jiménez-FonsecaPCarmona-BayonasAMartín-PérezESpanish Neuroendocrine Tumor Group (GETNE)Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumorsCancer Metastasis Rev201534338140026245646
   PubMed Web of Science ®Google Scholar
• ChanDLSegelovESinghSEverolimus in the management of metastatic neuroendocrine tumoursTher Adv Gastroenterol2017101132141
   Web of Science ®Google Scholar
• BurrisHALebrunFRugoHSHealth-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trialCancer2013119101908191523504821
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet Lond Engl20083729637449456
   PubMed Web of Science ®Google Scholar
• PavelMUngerNBorbathISafety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimusTarget Oncol201611566767527193465
   PubMed Web of Science ®Google Scholar
• YooCChoHSongMJEfficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumorCancer Chemother Pharmacol201779113914627942928
   PubMed Web of Science ®Google Scholar
• MorenoAAkcakanatAMunsellMFSoniAYaoJCMeric-BernstamFAntitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumorsEndocr Relat Cancer200815125726618310292
   PubMed Web of Science ®Google Scholar
• KulkeMRuszniewskiPvan CutsemEA randomized open-label phase II study of everolimus alone or in combination with pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial. Presented at the 12th Annual ENETS conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; Barcelona2015Neuroendocrinology102131
   Web of Science ®Google Scholar
• YaoJCPhanATFoglemanDRandomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarkerJ Clin Oncol201028 15s(sul;abstr4002)
   Web of Science ®Google Scholar
• KulkeMHNiedzwieckiDFosterNRRandomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance)J Clin Oncol201533 sul;abstr4005
   Web of Science ®Google Scholar
• YoungSLChaplinDJCombretastatin A4 phosphate: background and current clinical statusExpert Opin Investig Drugs200413911711182
   PubMed Web of Science ®Google Scholar
• WoodJMBoldGBuchdungerEPTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationCancer Res20006082178218910786682
   PubMed Web of Science ®Google Scholar
• XcoveryXcovery-Presents-Phase-1-Clinical-Results-at-ASCO [cited January 26, 2017] Available from: https://www.xcovery.com/wordpress/wp-content/uploads/Xcovery-Presents-Phase-1-Clinical-Results-at-ASCO.pdfAccessed May 22, 2017
   Google Scholar
• FuretPGuagnanoVFairhurstRADiscovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluationBioorg Med Chem Lett201323133741374823726034
   PubMed Web of Science ®Google Scholar
• McKianKPHaluskaPCixutumumabExpert Opin Investig Drugs200918710251033
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals OSI LLCTarceva (erlotinib) tablets [product information]Farmingdale, NYOSI Pharmaceuticals, LLC, an affiliate of Astellas Pharma US Inc2012
   Google Scholar
• MairaS-MStaufferFBrueggenJIdentification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activityMol Cancer Ther2008771851186318606717
   PubMed Web of Science ®Google Scholar
• HassanBAkcakanatASangaiTCatalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitorsOncotarget20145188544855725261369
   PubMedGoogle Scholar
• FaddenPHuangKHVealJMApplication of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90Chem Biol201017768669420659681
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMĆwikłaJBLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med2014371322423325014687
   PubMed Web of Science ®Google Scholar
• RaymondEDahanLRaoulJ-LSunitinib malate for the treatment of pancreatic neuroendocrine tumorsN Engl J Med2011364650151321306237
   PubMed Web of Science ®Google Scholar
• SunWLipsitzSCatalanoPMailliardJAHallerDGEastern Cooperative Oncology GroupPhase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281J Clin Oncol200523224897490416051944
   PubMed Web of Science ®Google Scholar
• FerollaPBrizziMPMeyerTEfficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA studyAnn Oncol201627suppl 6416O
   Google Scholar